Acta Neuropathologica

, Volume 125, Issue 6, pp 911–912 | Cite as

VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation

  • Jan Sperveslage
  • Midea Gierke
  • David Capper
  • Jürgen Honegger
  • Bence Sipos
  • Rudi Beschorner
  • Jens Schittenhelm

Activating BRAF mutations are observed in malignant melanomas, pleomorphic xanthoastrocytomas, hairy cell leukemia, papillary thyroid carcinomas, colorectal cancer, ovarian cancer and ganglioglioma [1, 10, 11]. Generation of a monoclonal antibody specific for the BRAF V600E mutation (VE1) was published recently [3]. This antibody has been successfully validated for melanomas [5], lung adenocarcinomas [8] and thyroid carcinomas [2]. Although pituitary adenomas account for up to 10 % of all intracranial tumors [4], there is still a lack of data on VE1 immunostains in these tumors. In three studies in which BRAF in pituitary adenomas was examined by sequencing, a single V600E mutation was found in 145 cases [6, 7, 10].

We screened 78 pituitary adenomas (epidemiological data in supplemental Table 1) with VE1 antibody. Staining was observed in 18 cases (12 weak (15 %); 5 moderate (6 %) and 1 strong case (1 %); supplemental Figure S1). Twelve of the positive cases were HGH-producing...


Adenoma Thyroid Carcinoma Pituitary Adenoma Papillary Thyroid Carcinoma Hairy Cell Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

401_2013_1118_MOESM1_ESM.pdf (808 kb)
Supplementary material 1 (PDF 809 kb)


  1. 1.
    Andrulis M et al (2012) Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 36:1796–1800PubMedCrossRefGoogle Scholar
  2. 2.
    Bullock M et al (2012) Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer 19:779–784PubMedCrossRefGoogle Scholar
  3. 3.
    Capper D et al (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122:11–19PubMedCrossRefGoogle Scholar
  4. 4.
    Central Brain Tumor Registry of the United States (2012) statistical report, revised March 23.
  5. 5.
    Colomba E et al (2013) Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 15:94–100PubMedCrossRefGoogle Scholar
  6. 6.
    De Martino I et al (2007) B-RAF mutations are a rare event in pituitary adenomas. J Endocrinol Invest 30: RC1–3Google Scholar
  7. 7.
    Ewing I et al (2007) A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol (Oxf) 66:348–352CrossRefGoogle Scholar
  8. 8.
    Ilie M et al (2013) Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 24:742–748PubMedCrossRefGoogle Scholar
  9. 9.
    Jeong D et al (2012) Detection of BRAFV600E mutations in papillary thyroid carcinomas by peptide nucleic acid clamp real-time pcr: a comparison with direct sequencing. Korean J Pathol 46:61–67PubMedCrossRefGoogle Scholar
  10. 10.
    Schindler G et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397–405PubMedCrossRefGoogle Scholar
  11. 11.
    Ziai J, Hui P (2012) BRAF mutation testing in clinical practice. Expert Rev Mol Diagn 12:127–138PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Jan Sperveslage
    • 2
  • Midea Gierke
    • 1
  • David Capper
    • 3
  • Jürgen Honegger
    • 4
  • Bence Sipos
    • 2
  • Rudi Beschorner
    • 1
  • Jens Schittenhelm
    • 1
  1. 1.Department of NeuropathologyUniversity of TuebingenTuebingenGermany
  2. 2.Institute of PathologyUniversity of TuebingenTuebingenGermany
  3. 3.Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Department of NeuropathologyUniversity of HeidelbergHeidelbergGermany
  4. 4.Department of NeurosurgeryUniversity of TuebingenTuebingenGermany

Personalised recommendations